J9347 HCPCS code: Injection, tremelimumab-actl, 1 mg
J9347 is the HCPCS Level II code for injection, tremelimumab-actl, 1 mg. In 2024 Medicare paid an average of $105.64 per service for J9347 across 128,006 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 300 per day on outpatient hospital claims. Medicare volume rose 160% from 2023 to 2024 (49,263 to 128,006 services). In 2024, about 408 clinicians billed Medicare for J9347 for 449 beneficiaries; Texas, California, Florida accounted for 55% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2023-07-01 |
| Last action effective | 2023-07-01 |
Who bills J9347 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 408 |
| Medicare beneficiaries | 449 |
| States with claims | 11 |
| Share of services in top 3 states (Texas, California, Florida) | 55% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9347, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 49,263 | 183 | $131.68 | $104.92 |
| 2024 | 128,006 | 449 | $132.59 | $105.64 |
States with the most J9347 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 18,675 | $106.41 |
| California | 15,225 | $106.42 |
| Florida | 15,024 | $106.29 |
| Virginia | 6,705 | $106.33 |
| Maryland | 6,600 | $101.52 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 300 | Prescribing Information |
| practitioner claims | 300 | Prescribing Information |
What changed for J9347
- 2023-07-01: J9347 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9347?
J9347 is the HCPCS Level II code for injection, tremelimumab-actl, 1 mg. Short descriptor: "Inj, tremelimumab-actl, 1 mg".
How much does Medicare pay for J9347?
In 2024, the average Medicare payment was $105.64 per service (average allowed $132.59).
Does Medicare cover J9347?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9347 can be billed per day?
300 on outpatient hospital claims; 300 on practitioner claims (NCCI medically unlikely edits).
Related J93 codes
- J9300 — Injection, gemtuzumab ozogamicin, 5 mg
- J9301 — Injection, obinutuzumab, 10 mg
- J9302 — Injection, ofatumumab, 10 mg
- J9303 — Injection, panitumumab, 10 mg
- J9304 — Injection, pemetrexed (pemfexy), 10 mg
- J9305 — Injection, pemetrexed, not otherwise specified, 10 mg
- J9306 — Injection, pertuzumab, 1 mg
- J9307 — Injection, pralatrexate, 1 mg
- J9308 — Injection, ramucirumab, 5 mg
- J9309 — Injection, polatuzumab vedotin-piiq, 1 mg
- J9310 — Injection, rituximab, 100 mg
- J9311 — Injection, rituximab 10 mg and hyaluronidase
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9347
- Watch J9347 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9347
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.